Exagen (XGN) Common Equity (2018 - 2026)

Exagen has reported Common Equity for 9 years, with the latest figure at $14.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 125.39% year-over-year to $14.4 million; the trailing twelve-month figure through Mar 2026 stood at $14.4 million (up 125.39% YoY), and the FY2025 full-year result was $17.4 million, up 82.9% from the prior year.
• Common Equity for Q1 2026 stood at $14.4 million, down from $17.4 million in the prior quarter.
• The five-year high for Common Equity was $76.2 million in Q1 2022, with the low at $6.4 million in Q1 2025.
• Historically, Common Equity has averaged $29.0 million across 5 years, with a median of $21.0 million in 2025.
• Annual changes were most pronounced in 2025 — Common Equity tumbled 67.97% — and 2026, when it soared 125.39%.
• Exagen's Common Equity stood at $42.5 million in 2022, then tumbled by 46.55% to $22.7 million in 2023, then sank by 57.96% to $9.5 million in 2024, then surged by 82.9% to $17.4 million in 2025, then slipped by 17.29% to $14.4 million in 2026.
• The last three Common Equity figures came in at $14.4 million (Q1 2026), $17.4 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.